ResearcherUniversity of KhartoumActive in the last 2 years

Khabab Abbasher Hussien Mohamed Ahmed

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0003-4608-5321; OpenAlex author ID A5089419481. Sources: OpenAlex.

Their work

Papers: 2 (first author 0, last author 1)
Trials: 0
Grants: 0
Labs led: 0
Collaborators: 4

Papers, trials and grants by year

2024: 1 paper · 2025: 1 paper

Papers 2

The Current Landscape of Pancreatic Cancer Management in Sub-Saharan Africa - A Perspective Review. Co-author DOI 10.1002/hsr2.71330 ↗
FDA endorses NALIRIFOX for metastatic pancreatic adenocarcinoma: an editorial. Last author DOI 10.1097/ms9.0000000000002564 ↗

Closest collaborators

The 4 strongest of 4 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

Hareesha Rishab Bharadwaj · 1 shared paper, 2025 · strength 0.30
- Paper The Current Landscape of Pancreatic Cancer Management in Sub-Saharan Africa - A Perspective Review. DOI 10.1002/hsr2.71330 ↗
Dushyant Singh Dahiya · 1 shared paper, 2025 · strength 0.30
- Paper The Current Landscape of Pancreatic Cancer Management in Sub-Saharan Africa - A Perspective Review. DOI 10.1002/hsr2.71330 ↗
Umar Akram · 1 shared paper, 2025 · strength 0.30
- Paper The Current Landscape of Pancreatic Cancer Management in Sub-Saharan Africa - A Perspective Review. DOI 10.1002/hsr2.71330 ↗
Wajiha Urooj · 1 shared paper, 2024 · strength 0.26
- Paper FDA endorses NALIRIFOX for metastatic pancreatic adenocarcinoma: an editorial. DOI 10.1097/ms9.0000000000002564 ↗

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.